Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory colorectal cancer. We conducted a phase 3 trial to further assess the efficacy and safety of TAS-102 in a global population of such patients. METHODS: In this double-blind study, we randomly assigned 800 patients, in a 2:1 ratio, to receive TAS-102 or placebo. The primary end point was overall survival. RESULTS: The median overall survival improved from 5.3 months with placebo to 7.1 months with TAS-102, and the hazard ratio for death in the TAS-102 group versus the placebo group was 0.68 (95% confidence interval [CI], 0.58 to 0.81; P<0.001). The most frequently observed clinically significant adverse events associated with TAS-102 were neutropenia, which occurred in 38% of those treated, and leukopenia, which occurred in 21%; 4% of the patients who received TAS-102 had febrile neutropenia, and one death related to TAS-102 was reported. The median time to worsening performance status (a change in Eastern Cooperative Oncology Group performance status [on a scale of 0 to 5, with 0 indicating no symptoms and higher numbers indicating increasing degrees of disability] from 0 or 1 to 2 or more) was 5.7 months with TAS-102 versus 4.0 months with placebo (hazard ratio, 0.66; 95% CI, 0.56 to 0.78; P<0.001). CONCLUSIONS: In patients with refractory colorectal cancer, TAS-102, as compared with placebo, was associated with a significant improvement in overall survival. (Funded by Taiho Oncology-Taiho Pharmaceutical; RECOURSE ClinicalTrials.gov number, NCT01607957.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Third-line treatment options are limited to regorafenib and trifluridine–tipiracil, which have extended median overall survival by less than 2 months over placebo and have been associated with a low response rate (<2%) and median progression-free survival of approximately 2 months, outcomes that highlight the need for new approaches.15,16”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (2023) · cites this paper as [16]
In the citing paper
“Findings in the monotherapy cohort also compared favorably with the results of a trial of regorafenib (another third-line treatment) involving 505 patients, who had a response of 1.0%, progression-free survival of 1.9 months, and overall survival of 6.4 months.15,16”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (2023) · cites this paper as [16]
In the citing paper
“As described in the drug package insert, the efficacy and safety have not been established in the primary or secondary treatments [99, 100].”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [100]
In the citing paper
“Nevertheless, single-agent garsorasib and the combination of garsorasib and cetuximab achieved considerable ORRs of 19.2% and 45.2%, and a trend toward prolonged PFS and OS, as compared with the standard-of-care includes regorafenib and trifluridine/tipiracil, which demonstrated an ORR of 1.0% and 1.6%, respectively.30,31”
In the citing paper
“The phase 3 RECOURCE trial evaluated TAS-102 vs. placebo in metastatic CRC patients refractory to standard chemotherapies [44]. TAS-102 significantly improved mOS to 7.1 months compared to 5.3 months with placebo (HR for death: 0.68, 95% CI 0.58–0.81).”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [44]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,043
Self-citationSystemic Therapy for Colorectal Cancer
Varghese, A. M. (2019) · DeckerMed CGSO Case-Based Reviews · doi:10.2310/cgso.16189 · Cited by 883
Use of Statins and the Risk of Death in Patients With Prostate Cancer
Yu, O., Eberg, M., Benayoun, S., Aprikian, A., Batist, G., Suissa, S., & Azoulay, L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4757 · Cited by 659
Yoshino, T., Mizunuma, N., Yamazaki, K., Nishina, T., Komatsu, Y., Baba, H., Tsuji, A., Yamaguchi, K., Muro, K., Sugimoto, N., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70345-5 · Cited by 326
Self-citationFukushima, M., Suzuki, N., Emura, T., Yano, S., Kazuno, H., Tada, Y., Yamada, Y., & Asao, T. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00253-7 · Cited by 239
Tanaka, N., Sakamoto, K., Okabe, H., Fujioka, A., Yamamura, K., Nakagawa, F., Nagase, H., Yokogawa, T., Oguchi, K., Ishida, K., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3487 · Cited by 149
Emura, T., Suzuki, N., Yamaguchi, M., Ohshimo, H., & Fukushima, M. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.3.571 · Cited by 120
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells
Emura, T., Murakami, Y., Nakagawa, F., Fukushima, M., & Kitazato, K. (2004) · International Journal of Molecular Medicine · doi:10.3892/ijmm.13.4.545 · Cited by 104
Research works printed but not linked: 6
- Sobrero A, 2000, Semin Oncol, 27, 72
- Emura T, 2004, Int J Mol Med, 13, 545
- Emura T, 2004, Int J Oncol, 25, 571
- Heidelberger C, 1964, Cancer Res, 24, 1979
- Heidelberger C, 1965, Cancer Res, 25, 377
- Dexter DL, 1972, Cancer Res, 32, 247
Cited by
Items 601–700 of 1,000
Nukatsuka, M., Fujioka, A., Nagase, H., Tanaka, G., & Hayashi, H. (2023) · Chemotherapy · doi:10.1159/000528867 · Cited by 14
Montés, A. F., Alonso, V., Aranda, E., Élez, E., Alfonso, P., Grávalos, C., Maurel, J., Vera, R., Vidal, R., & Aparicio, J. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03199-1 · Cited by 16
Ren, L., Zhu, D., Gu, J. F., Jia, B., Li, J., Qin, X., Wang, X., Xu, R., Ye, Y., Zhang, S., et al. (2023) · Clinical Surgical Oncology · doi:10.1016/j.cson.2023.100013 · Cited by 12
A synthetic control arm for refractory metastatic colorectal cancer: the no placebo initiative
Yoshino, T., Shi, Q., Misumi, T., Bando, H., Wakabayashi, M., Raeisi, M., André, T., & de Gramont, A. (2023) · Nature Medicine · doi:10.1038/s41591-023-02488-0 · Cited by 13
Self-citationLi, L., Wang, T., Wu, Z., Li, Y., Ma, H., Wang, L., Lei, S., & Chen, W. (2023) · Translational Cancer Research · doi:10.21037/tcr-23-867 · Cited by 11
Bai, M., Lu, Y., Shi, C., Yang, J., Li, W., Yin, X., Huang, C., Shen, L., Xie, L., & Ba, Y. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0301 · Cited by 9
Hanna, D. L., & Lenz, H. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1172961 · Cited by 11
Self-citationRaedler, L. A. (2016) · Europe PMC (PubMed Central) · Cited by 10
Advanced colorectal cancer treatment options beyond standard systemic therapy
Price, T. J. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30002-5 · Cited by 10
Kieler, M., Scheithauer, W., Zielinski, C. C., Chott, A., Al-Mukhtar, A., & Prager, G. W. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000084 · Cited by 12
Nakanishi, R., Kitao, H., Kiniwa, M., Morodomi, Y., Iimori, M., Kurashige, J., Sugiyama, M., Nakashima, Y., Saeki, H., Oki, E., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17282-5 · Cited by 10
Suenaga, M., Wakatsuki, T., Mashima, T., Ogura, M., Ichimura, T., Shinozaki, E., Nakayama, I., Osumi, H., Ota, Y., Takahari, D., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00749-9 · Cited by 10
Strickler, J. H., Rushing, C. N., Niedzwiecki, D., McLeod, A., Altomare, I. P., Uronis, H. E., Hsu, S. D., Zafar, S. Y., Morse, M. A., Chang, D. Z., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6234-8 · Cited by 10
Roviello, G., Fancelli, S., Michelet, M. R. G., Aprile, G., Nobili, S., Roviello, F., Cianchi, F., Mini, E., & Lavacchi, D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102987 · Cited by 10
Saleh, M. N., Cassier, P. A., Eberst, L., Naik, G., Morris, V. K., Pant, S., Terret, C., Gao, L., Long, A. J., Mao, H., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0520 · Cited by 10
Gutting it Out: Developing Effective Immunotherapies for Patients With Colorectal Cancer
Gorgulho, C. M., Krishnamurthy, A., Lanzi, A., Galon, J., Housseau, F., Kaneno, R., & Lotze, M. T. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000357 · Cited by 16
Zaniboni, A., Barone, C. A., Banzi, M. C., Bergamo, F., Blasi, L., Bordonaro, R., Bartolomeo, M. D., Costanzo, F. D., Frassineti, G. L., Garufi, C., et al. (2021) · Future Oncology · doi:10.2217/fon-2020-1278 · Cited by 10
Self-citationKostos, L. K., Hong, W., Lee, B., Tran, B., Lok, S. W., Anton, A., Gard, G., To, Y. H., Wong, V., Shapiro, J. D., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33568 · Cited by 12
Self-citationChan, B. M., Höchster, H. S., & Lenz, H. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxy006 · Cited by 10
Self-citationLiver-Directed and Systemic Therapies for Colorectal Cancer Liver Metastases
Kemeny, N. E., Kurilova, I., Li, J., Camacho, J. C., & Sofocleous, C. T. (2019) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-019-02284-9 · Cited by 10
Masuishi, T., Taniguchi, H., Kawakami, T., Kawamoto, Y., Kadowaki, S., Onozawa, Y., Muranaka, T., Tajika, M., Yasui, H., Nakatsumi, H., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000584 · Cited by 10
Self-citationTrifluridine/tipiracil for the treatment of metastatic gastric cancer
Kawazoe, A., & Shitara, K. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1715209 · Cited by 10
Li, B., Yang, W., Liu, N., Bi, D., Yang, T., Wu, G., & Sun, Y. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02885-3 · Cited by 8
Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma
Than, M. T., Dequiedt, L., Sor, R., Nair, S., Markosyan, N., Furth, E. E., Yang, C., Ray-Fofana, C., Menard, M. J., Quintana, E., et al. (2026) · Science · doi:10.1126/science.aec7929 · Cited by 13
New active drugs for the treatment of advanced colorectal cancer
Zaniboni, A. (2015) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v7.i12.356 · Cited by 9
Self-citationSu, G.-L., Wang, Y. Y., Wang, J., & Liu, H. (2020) · Journal of International Medical Research · doi:10.1177/0300060520926408 · Cited by 9
Yamazaki, K., Yuki, S., Oki, E., Sano, F., Makishima, M., Aoki, K., Hamano, T., & Yamanaka, T. (2021) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2021.03.001 · Cited by 11
Self-citationTucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer
Ahn, D. H., Walden, D. M., & Bekaii‐Saab, T. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2053107 · Cited by 9
Ree, A. H., Mælandsmo, G. M., Flatmark, K., Russnes, H. G., Castañeda, M. G., & Aas, E. (2022) · Acta Oncologica · doi:10.1080/0284186x.2022.2098053 · Cited by 9
Nie, C., Xu, W., Chen, B., Lv, H., Wang, J., Liu, Y., He, Y., Wang, S., Zhao, J., & Chen, X. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.11.005 · Cited by 10
Matsumoto, T., Ikoma, T., Yamamura, S., Miura, K., Tsuduki, T., Watanabe, T., Nagai, H., Takatani, M., & Yasui, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-29706-6 · Cited by 9
Beyond EGFR inhibitors in advanced colorectal cancer: Targeting BRAF and HER2
Dao, V. A., & Heestand, G. M. (2023) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2023.100960 · Cited by 9
Devall, M. A. M., Ali, M. W., Eaton, S. D., Weisenberger, D. J., Reilley, M. J., Powell, S. M., Li, L., & Casey, G. (2023) · Cancer Medicine · doi:10.1002/cam4.6048 · Cited by 9
Kröning, H., Göhler, T., Decker, T. W., Grundeis, M., Kojouharoff, G., Lipke, J., Semsek, D., Moorahrend, E., Sauer, A., Bruch, H., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34603 · Cited by 19
Kennedy, A. S., Brown, D. B., Fakih, M., Jeyarajah, R., Jones, S. F., Liu, D. M., Pinato, D. J., Sangro, B., Sharma, N., Sze, D. Y., et al. (2024) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2024.06.006 · Cited by 9
Saeed, A., Tabernero, J. M., Parikh, A. R., den Eynde, M. V., Karthaus, M., Gerlinger, M., Wang, Z., Wang, G., Smith, R., & Hecht, J. R. (2024) · Future Oncology · doi:10.1080/14796694.2024.2352276 · Cited by 10
Self-citationThe Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed
Hernando-Cubero, J., Matos, I. G., Alonso-Orduña, V., & Capdevila, J. (2017) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-017-9946-5 · Cited by 9
Saif, M. W., Rosen, L. S., Rudek, M. A., Sun, W., Shepard, D. R., Becerra, C. R., Yamashita, F., Bebeau, P., & Winkler, R. E. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13856 · Cited by 9
Devaux, M., Gérard, L., Richard, C., Bengrine-Lefèvre, L., Vincent, J., Schmitt, A., & Ghiringhelli, F. (2019) · World Journal of Clinical Oncology · doi:10.5306/wjco.v10.i2.75 · Cited by 10
Zhou, K., Zhou, J., Zhang, M., Liao, W., & Li, Q. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02127-6 · Cited by 9
Carriles, C., Jiménez‐Fonseca, P., Cánovas, M. S., Pimentel, P. C. B., Carmona‐Bayonas, A., García, T., Álvarez, M. C., & Blázquez, A. L. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02154-3 · Cited by 9
Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field
Marhold, M., Topakian, T., Agis, H., Bartsch, R., Berghoff, A. S., Brodowicz, T., Fuereder, T., Ilhan‐Mutlu, A., Kiesewetter, B., Krainer, M., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000880 · Cited by 9
Brennan, V. K., Colaone, F., Shergill, S., & Pollock, R. F. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2020.1839273 · Cited by 9
Bang, Y. H., Kim, J. E., Lee, J. S., Kim, S. Y., Kim, K., Kim, T. W., & Hong, Y. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-86482-x · Cited by 9
Prager, G. W., Köhne, C., O’Connor, J. M., Rivera, F., Santini, D., Wasan, H. S., & Phelip, J. (2021) · Current Oncology · doi:10.3390/curroncol28030194 · Cited by 10
Lessons Learned in Managing Patients with Colorectal Cancer During the COVID-19 Pandemic
Mukherji, R., & Marshall, J. L. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00888-3 · Cited by 9
Medication adherence reporting in pivotal clinical trials: overview of oral oncological drugs
Lasala, R., Santoleri, F., Romagnoli, A., Abrate, P., Musicco, F., & Costantini, A. (2022) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2021-002998 · Cited by 9
Antoniotti, C., Marmorino, F., Boccaccino, A., Martini, S., Antista, M., Rossini, D., Zuco, V., Prisciandaro, M., Conca, V., Zucchelli, G., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.01.025 · Cited by 10
CCDC12 promotes tumor development and invasion through the Snail pathway in colon adenocarcinoma
Du, F., Peng, L., Wang, Q., Dong, K., Pei, W., Zhuo, H., Xu, T., Jing, C., Li, L., & Zhang, J. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04617-y · Cited by 10
Philipovskiy, A. V., Ghafouri, S. R., Dwivedi, A. K., Alvarado, L. A., McCallum, R. W., Maegawa, F. B., Konstantinidis, I. T., Hakim, N., Shurmur, S. W., Awasthi, S., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.772225 · Cited by 9
Lu, Y., Deng, S., Dou, Q.-Y., Pan, W., Liu, Q., Ji, H., Wang, X., & Zhang, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.885699 · Cited by 9
Sommerhäuser, G., Kurreck, A., Stintzing, S., Heinemann, V., von Weikersthal, L. F., Dechow, T. N., Kaiser, F., Karthaus, M., Schwaner, I., Fuchs, M., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09892-8 · Cited by 9
Regional Variations in Clinical Trial Outcomes in Oncology.
Wilson, B. E., Pearson, S., Barton, M., & Amir, E. (2022) · The Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7029 · Cited by 7
Dueland, S., Smedman, T. M., Grut, H., Syversveen, T., Jørgensen, L. H., & Line, P. (2022) · Cancers · doi:10.3390/cancers14205042 · Cited by 9
Javaid, S., Ishtiaq, M., Shaikh, M., Hameed, A., & Choudhary, M. I. (2016) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2016.11.007 · Cited by 9
Wang, D. S., Louie, J. D., & Sze, D. Y. (2019) · Techniques in vascular and interventional radiology · doi:10.1053/j.tvir.2019.02.007 · Cited by 9
Matsuhashi, N., Takahashi, T., Fujii, H., Suetsugu, T., Fukada, M., Iwata, Y., Tokumaru, Y., Imai, T., Mori, R., Tanahashi, T., et al. (2019) · Molecular and Clinical Oncology · doi:10.3892/mco.2019.1899 · Cited by 10
Chemotherapy rechallenge in metastatic colon cancer: A case report and literature review
Reddy, T. P., Khan, U., Burns, E. A., & Abdelrahim, M. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i11.959 · Cited by 9
Radioembolization of Secondary Hepatic Malignancies
Manchec, B., Kokabi, N., Narayanan, G., Niekamp, A., Peña, C., Powell, A., Schiro, B. J., & Gandhi, R. T. (2021) · Seminars in Interventional Radiology · doi:10.1055/s-0041-1732318 · Cited by 9
Wang, C., Tang, Y., Ma, H., Wei, S., Hu, X., Zhao, L., & Wang, G. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.919389 · Cited by 10
Kita, K., & Burdowski, A. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i13.1780 · Cited by 9
Gao, L., Tang, L., Hu, Z., Peng, J., Li, X., & Liu, B. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1269203 · Cited by 11
Rais, T., Riaz, R., Siddiqui, T., Shakeel, A., Khan, A., & Zafar, H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1296765 · Cited by 10
Zheng, K., Zhu, X., Xu, L., Cao, G., Niu, C., Yan, X., Xu, D., Liu, W., Bao, Q., Wang, L., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1420956 · Cited by 8
Cisek, P., Kuncman, Ł., Jereczek-Fossa, B. A., Wojtyna, E., Orzechowska, M., Sroka, S., Kordzińska‐Cisek, I., Fijuth, J., & Bilski, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-09227-0 · Cited by 8
Pellatt, A. J., Bent, A. H., Hornstein, N. J., Parseghian, C. M., Huey, R. W., Raghav, K. P. S., Morris, V. K., Overman, M. J., Morelli, P., Willis, J. A., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00142 · Cited by 9
Hoyek, C., Naqvi, S. A. A., Sahwan, O., Jamal, F., Faisal, K. S., Pirozzi, A., Pathak, S., Almader‐Douglas, D., Borad, M. J., Wu, C., et al. (2025) · Digestive and Liver Disease · doi:10.1016/j.dld.2025.09.024 · Cited by 9
Zhang, W., Gong, C., Huang, J., Liu, T., Sun, Y., Jiang, Z., Qu, W., Yang, L. F., Xin, Y., Zhao, F., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04237-3 · Cited by 7
Schouten, J. F., Willems, J., Sanders, S. J. W. J., Creemers, G., & Deenen, M. J. (2021) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2021.09.004 · Cited by 8
Coutzac, C., Trouilloud, I., Artru, P., Henriques, J., Masson, T., Doat, S., Bouché, O., Coriat, R., Saint, A., Moulin, V., et al. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2021.12.003 · Cited by 10
Value-Based Analysis of Therapies in Refractory Metastatic Colorectal Cancer in US
Cho, S. K., Bekaii‐Saab, T., Kavati, A., Babajanyan, S., Hocum, B. T., & Barzi, A. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.09.003 · Cited by 9
New Developments in Treating RAS-Mutated Metastatic Colorectal Cancer
Janssens, K., Lambrechts, C., Geerinckx, B., de Beeck, K. O., Camp, G. V., Oliveres, H., Prenen, H., Vandamme, T., & Peeters, M. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01095-y · Cited by 10
Self-citationKito, Y., Kawakami, H., Mitani, S., Nishina, S., Matsumoto, T., Tsuzuki, T., Shinohara, Y., Shimokawa, H., Kumanishi, R., Ohta, T., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad296 · Cited by 11
Self-citationNew options for late-line treatment of metastatic colorectal cancer
Lonardi, S., & Pietrantonio, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00881-1 · Cited by 8
Shitara, K., Falcone, A., Fakih, M., George, B., Sundar, R., Ranjan, S., & Cutsem, E. V. (2024) · The Oncologist · doi:10.1093/oncolo/oyae007 · Cited by 8
Self-citationBekaii‐Saab, T. (2024) · The American Journal of Managed Care · doi:10.37765/ajmc.2024.89545 · Cited by 11
Sobrero, A. F., Dasari, A. N., Aquino, J., Lonardi, S., García‐Carbonero, R., Élez, E., Yoshino, T., Yao, J. C., Alfonso, P. G., Kocsis, J., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115268 · Cited by 8
Self-citationCirculating tumor DNA: A new tool to predict recurrence and guide treatment of colorectal cancer
Quang, E. V., Gandini, A., Taly, V., Laurent‐Puig, P., Zaanan, A., & Taïeb, J. (2025) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2025.102611 · Cited by 10
Modest, D. P., Ricard, I., Stintzing, S., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al-Batran, S.-E., Heintges, T., Kahl, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.030 · Cited by 8
Makihara, K., Fukui, R., UCHIYAMA, H., Shigeoka, Y., & Toyokawa, A. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2019.04.04 · Cited by 8
Cicero, G., Addeo, R., Luca, R. D., Re, G. L., Gulotta, L., Marchesa, P., & Gulotta, G. (2020) · Drugs in Context · doi:10.7573/dic.2020-6-3 · Cited by 8
Huemer, F., Piringer, G., Schlintl, V., Hackl, H., Rinnerthaler, G., Thaler, J., Greil, R., & Weiß, L. (2020) · Cancers · doi:10.3390/cancers12102812 · Cited by 8
Malik, M., Michalak, M., Radecka, B. S., Gełej, M., Jackowska, A., Filipczyk−Cisarż, E., Hetman, K., Foszczyńska‐Kłoda, M., Kania-Zembaczyńska, B., Mańka, D., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215107 · Cited by 11
Liang, Y., Liang, J., Lin, B., Huang, J. C., Hung, J., Lai, S.-L., Chen, T., Tsai, J., Cheng, Y., Tsao, T.-H., et al. (2022) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2022.02.019 · Cited by 8
Development of Tissue-Agnostic Treatments for Patients with Cancer
Lemery, S. J., Fashoyin‐Aje, L. A., Marcus, L. J., Casak, S. J., Schneider, J. A., Theoret, M. R., Kluetz, P. G., Pazdur, R., & Beaver, J. A. (2022) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-060921-021828 · Cited by 8
Feng, A., Guo, J., Gao, S., Kou, F., Liu, S.-X., Liu, P., Chen, H., Wang, X., Xu, H., Cao, G., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.913017 · Cited by 8
Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers
Gonzalez, N. S., Castet, F., Élez, E., Macarulla, T. M., & Tabernero, J. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1021772 · Cited by 10
Self-citationAngiogenesis inhibition in metastatic colorectal cancer continuum of care
Martinelli, E., & Ciardiello, F. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00867-x · Cited by 8
Review on TAS-102 development and its use for metastatic colorectal cancer
Mota, J. M., da Fonseca, L. G., Braghiroli, M. I., & Hoff, P. M. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.05.015 · Cited by 8
Karasic, T. B., Rosen, M. A., & O'Dwyer, P. J. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3389-3 · Cited by 8
McGregor, M., & Price, T. J. (2018) · Future Oncology · doi:10.2217/fon-2017-0711 · Cited by 10
IMblaze 370: lessons learned and future strategies in colorectal cancer treatment
McGregor, M., & Price, T. J. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.08.119 · Cited by 9
Iveson, T. J., Carter, A. M., Shiu, K., Spooner, C., Stevens, D. J., & Mullamitha, S. (2020) · BMC Cancer · doi:10.1186/s12885-020-6577-1 · Cited by 8
Kim, R. D., Azad, N. S., Morse, M. A., Poplin, E. A., Mahipal, A., Tan, B. R., Mavroukakis, S. A., Fantini, M. C., Tsang, K. Y., Zaki, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0426 · Cited by 8
Wu, Y., Fan, Y., Dong, D., Dong, X., Hu, Y. J., Shi, Y., Jing, J., & Li, E. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920940932 · Cited by 8
Pietrantonio, F., Fucà, G., Manca, P., Pagani, F., Raimondi, A., Prisciandaro, M., Randon, G., Corti, F., de Braud, F., Cremolini, C., et al. (2020) · Tumori Journal · doi:10.1177/0300891620960808 · Cited by 8
Watanabe, J., Sasaki, S., Kusumoto, T., Sakamoto, Y., Yoshida, K., Tomita, N., Maeda, A., Teshima, J., Yokota, M., Tanaka, C., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100077 · Cited by 8
Saif, M. W., Becerra, C. R., Fakih, M., Sun, W., POPOVIC, L. S., Krishnamurthi, S., George, T. J., Rudek, M. A., Shepard, D. R., Škopek, J., et al. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04308-z · Cited by 9
Leal, A. D., Krishnamurthy, A., Head, L., & Messersmith, W. A. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1541085 · Cited by 9
Hefnawy, M., Alzamil, A., Abuelizz, H. A., & Al-Shehri, M. M. (2019) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2019.09.004 · Cited by 8
Metadata
- Authors
- Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., Sobrero, A., Boucher, E., Peeters, M., Tran, B., Lenz, H.-J., Zaniboni, A., Hochster, H., Cleary, J. M., Prenen, H., Benedetti, F., Mizuguchi, H., Makris, L., Ito, M., & Ohtsu, A.
- Affiliations
- University of Pisa (IT)
- National Cancer Center Hospital East (JP)
- Centre Eugène Marquis (FR)
- The Royal Melbourne Hospital (AU)
- USC Norris Comprehensive Cancer Center (US)
- Yale Cancer Center (US)
- Taiho Oncology (United States) (US)
- Ospedale Policlinico San Martino (IT)
- Antwerp University Hospital (BE)
- University of Southern California (US)
- Fondazione Poliambulanza Istituto Ospedaliero (IT)
- Dana-Farber Cancer Institute (US)
- KU Leuven (BE)
- Taiho Pharmaceutical (Japan) (JP)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-05-14
- Volume
- 372
- Issue
- 20
- Pages
- 1909-1919
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W242040007
- Semantic Scholar
- 3d08304a7bda1c2d5aa4ab9b3aa96bc534c22f58
- Cited by
- 1,431
- References
- 20
- Citations by year
- 2026: 97 · 2025: 136 · 2024: 165 · 2023: 145 · 2022: 150 · 2021: 138 · 2020: 150 · 2019: 112 · 2018: 115 · 2017: 116 · 2016: 79 · 2015: 27
- FWCI
- 49.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- trifluridine/tipiracil, trifluridine, tipiracil, metastatic colorectal cancer, refractory colorectal cancer, oral chemotherapy, overall survival, neutropenia, leukopenia, febrile neutropenia, performance status, drug safety
- MeSH terms
- Adenocarcinoma, Adult, Aged, Aged, 80 and over, Double-Blind Method, Drug Combinations, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Pyrrolidines, Thymine, Trifluridine, Uracil, Colorectal Neoplasms, Proportional Hazards Models, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.